| Autor: |
Zafrani, Lara, Canet, Emmanuel, Walter-Petrich, Anouk, Joly-Laffargue, Bérangère, Veyradier, Agnès, Faguer, Stanislas, Bigé, Naïke, Calvet, Laure, Mayaux, Julien, Grangé, Steven, Rafat, Cédric, Poulain, Coralie, Klouche, Kada, Perez, Pierre, Pène, Frédéric, Pichereau, Claire, Duceau, Baptiste, Mariotte, Eric, Chevret, Sylvie, Azoulay, Elie |
| Předmět: |
|
| Zdroj: |
Intensive Care Medicine; Nov2023, Vol. 49 Issue 11, p1293-1304, 12p |
| Abstrakt: |
Purpose: Studies have suggested benefits from magnesium sulphate in thrombotic thrombocytopenic purpura (TTP). We aimed to measure the effects of magnesium sulphate supplementation on TTP recovery. Methods: In this multicenter, randomised, double-blind, controlled, superiority study, we enrolled adults with a clinical diagnosis of TTP. Patients were randomly allocated to receive magnesium sulphate (6 g intravenously followed by a continuous infusion of 6 g/24 h for 3 days) or placebo, in addition to the standard treatment. The primary outcome was the median time to platelet normalisation (defined as a platelet count ≥ 150 G/L). Efficacy and safety were assessed by intention-to-treat. Results: Overall, we enrolled 74 participants, including one who withdrew his/her consent. Seventy-three patients were further analyzed, 35 (48%) allocated to magnesium sulphate and 38 (52%) to placebo. The median time to platelet normalisation was 4 days (95% confidence interval [CI], 3–4) in the magnesium sulphate group and 4 days (95% CI 3–5) in the placebo group. The cause-specific hazard ratio of response was 0.93 (95% CI 0.58–1.48, p = 0.75). The number of patients with ≥ 1 serious adverse reactions was similar in the two groups. By day 90, four patients in the magnesium sulphate group and two patients in the placebo group had died (p = 0.42). The most frequent adverse event was low blood pressure occurring in 34% in the magnesium sulphate group and 29% in the placebo group (p = 0.80). Conclusion: Among patients with TTP, the addition of magnesium sulphate to the standard of care did not result in a significant improvement in time to platelet normalisation. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink